Where are we now?12 Aug 2020 20:49
How much did the previous management pull the wool over our eyes?
Is 401 actually worth anything? A trial with 7 patients didn't convince many people.
Who are BlackCat and have they got any money yet? Where have the 6 partners gone?
201 appeared so promising, but again the size of the data set is a big question. Have enough patients now been recruited and tested to produce any convincing evidence beyond safety? It has dragged out a long time now.
Is BC201 anything more than an unstarted project?
Perhaps 301 will surprise us?
At least there is money in the pot to put things right, but we may find that a £20m valuation is unrealistic at present. We have prevciously reached the giddy heights of a £27m MCAP - ie 50p a share, but then we thought 3 years ago that 201 and 401 were potential blockbusters that were about to report good data.
They still may do, but I remain invested and cautious. Roll on 41p to break even, but I may have to wait several more years.